Reports Q1 revenue $52.6M, consensus $52.07M. “We are pleased with the positive customer responses to our three new specialized bunion systems targeting all four classes of bunion deformities while we continue to expand our differentiated body of clinical evidence and drive adoption of our flagship Lapiplasty and Adductoplasty procedures. Our first quarter results represent solid growth versus a difficult comp and strong improvements in adjusted EBITDA,” said John Treace, CEO, Founder and Board Member of Treace. “Looking ahead, our expanding best in class bunion portfolio and robust innovation pipeline along with significant surgeon training momentum positions Treace for accelerating growth throughout the year and to extend our leadership position within the US bunion market.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMCI:
- Class Action Filed Against Treace Medical Concepts, Inc. (TMCI) – June 10, 2025 Deadline to Join – Contact Levi & Korsinsky LLP
- Treace Medical price target lowered to $14 from $16 at BTIG
- Treace Medical price target lowered to $8 from $9.50 at Truist
- Treace Medical Concepts CEO to Become Board Chairman
- Treace Medical appoints John Treace as chairman of the board